4 results on '"Margherita Gaudenzi"'
Number of results to display per page
Search Results
2. Heart failure in COVID‐19: the multicentre, multinational PCHF‐COVICAV registry
- Author
-
Mateusz Sokolski, Sander Trenson, Justyna M. Sokolska, Domenico D'Amario, Philippe Meyer, Nana K. Poku, Tor Biering‐Sørensen, Mats C. Højbjerg Lassen, Kristoffer G. Skaarup, Eduardo Barge‐Caballero, Anne‐Catherine Pouleur, Davide Stolfo, Gianfranco Sinagra, Klemens Ablasser, Viktoria Muster, Peter P. Rainer, Markus Wallner, Alessandra Chiodini, Pascal S. Heiniger, Fran Mikulicic, Judith Schwaiger, Stephan Winnik, Huseyin A. Cakmak, Margherita Gaudenzi, Massimo Mapelli, Irene Mattavelli, Matthias Paul, Irina Cabac‐Pogorevici, Claire Bouleti, Marzia Lilliu, Chiara Minoia, Jeroen Dauw, Jérôme Costa, Ahmet Celik, Nathan Mewton, Carlos E.L. Montenegro, Yuya Matsue, Goran Loncar, Michal Marchel, Aris Bechlioulis, Lampros Michalis, Marcus Dörr, Edgard Prihadi, Felix Schoenrath, Daniel R. Messroghli, Wilfried Mullens, Lars H. Lund, Giuseppe M.C. Rosano, Piotr Ponikowski, Frank Ruschitzka, and Andreas J. Flammer
- Subjects
COVID‐19 ,SARS‐CoV2 ,Heart failure ,Cardiovascular disease ,Risk factors ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims We assessed the outcome of hospitalized coronavirus disease 2019 (COVID‐19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations. Methods and results International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID‐19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF‐COVICAV). The primary endpoint was in‐hospital mortality. Of 1974 patients hospitalized with COVID‐19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62–81] years, 58% male), with HF being present in 256 [20%] patients. Overall in‐hospital mortality was 25% (n = 323/1282 deaths). In‐hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non‐HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44–2.59], P
- Published
- 2021
- Full Text
- View/download PDF
3. Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry
- Author
-
Nathan Mewton, Tor Biering-Sørensen, Marcus Dörr, Andreas J. Flammer, Michał Marchel, Wilfried Mullens, Domenico D'Amario, Yuya Matsue, Huseyin A. Cakmak, Gianfranco Sinagra, Davide Stolfo, Kristoffer Grundtvig Skaarup, Claire Bouleti, Marzia Lilliu, Felix Schoenrath, Edgard Prihadi, Irene Mattavelli, Justyna M. Sokolska, Carlos Eduardo Lucena Montenegro, Daniel Messroghli, Anne-Catherine Pouleur, Frank Ruschitzka, Matthias Paul, Nana K. Poku, Lampros K. Michalis, Mateusz Sokolski, Jérôme Costa, Alessandra Chiodini, Viktoria Muster, Jeroen Dauw, Goran Loncar, Peter P. Rainer, Philippe Meyer, Eduardo Barge-Caballero, Massimo Mapelli, Aris Bechlioulis, Fran Mikulicic, Ahmet Çelik, Piotr Ponikowski, Klemens Ablasser, Chiara Minoia, Judith Schwaiger, Sander Trenson, Markus Wallner, Lars Lund, Giuseppe M.C. Rosano, P S Heiniger, Mats Christian Højbjerg Lassen, Margherita Gaudenzi, Irina Cabac-Pogorevici, Stephan Winnik, University of Wrocław [Poland] (UWr), University hospital of Zurich [Zurich], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Geneva University Hospital (HUG), Herlev and Gentofte Hospital, University of Copenhagen = Københavns Universitet (UCPH), Complejo Hospitalario Universitario A Coruña [A Coruña, Spain] (CHUAC), Instituto de Investigación Biomédica de A Coruña [La Corogne, Espagne] (INIBIC), A Coruña University Hospital [La Corogne, Espagne], Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares [Spain] (CIBERCV), Cliniques universitaires St Luc [Bruxelles], Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain = Catholic University of Louvain (UCL), Università degli studi di Trieste = University of Trieste, Medical University of Graz, Temple University [Philadelphia], Pennsylvania Commonwealth System of Higher Education (PCSHE), Center for Biomarker Research in Medicine [Graz, Austria] (CBmed GmbH), Mustafakemalpasa State Hospital [Bursa, Turkey] (MSH), Centro Cardiologico Monzino [Milano], Dpt di Scienze Cliniche e di Comunità [Milano] (DISCCO), Università degli Studi di Milano = University of Milan (UNIMI)-Università degli Studi di Milano = University of Milan (UNIMI)-Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Università degli Studi di Milano = University of Milan (UNIMI), Johns Hopkins University Applied Physics Laboratory [Laurel, MD] (APL), Luzerner Kantonsspital [Lucerne, Switzerland] (LUKS), University Nicolae Testemitanu [Kishinev, Moldova] (UNT), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital 'Magalini' Villafranca - ULSS 9 Scaligera [Verona, Italy], Public Health Company Valle Olona [Busto Arsizio, Italy] (PHCVO), Ziekenhuis Oost-Limburg (ZOL), Hasselt University (UHasselt), Centre Hospitalier Universitaire de Reims (CHU Reims), Mersin University, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL), Centre d'Investigation Clinique [Bron] (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est [Bron], Universidade Federal de Pernambuco [Recife] (UFPE), Juntendo University Hospital [Tokyo], Institute for Cardiovascular Diseases Dedinje [Belgrade, Serbia] (IC2D), University of Belgrade [Belgrade], Medical University of Warsaw - Poland, University Hospital of Ioannina, University of Medicine Greifswald, German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), ZNA Heart Centre [Antwerp, Belgium], German Heart Institute Berlin [Berlin, Germany] (GHIB), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Deutsches Herzzentrum Berlin, Karolinska Institute, Karolinska University Hospital [Stockholm], IRCCS San Raffaele [Rome, Italy], Wrocław Medical University, CarMeN, laboratoire, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de cardiologie, Mapelli, Massimo/0000-0001-9985-7407, celik, Ahmet/0000-0002-9417-7610, Sokolski, Mateusz/0000-0001-9925-3566, Sokolska, Justyna/0000-0002-4759-5879, Lassen, Mats/0000-0002-2255-582X, Skaarup, Kristoffer/0000-0002-2690-7511, Sokolski, Mateusz, Trenson, Sander, Sokolska, Justyna M., D'Amario, Domenico, Meyer, Philippe, Poku, Nana K., Biering-Sorensen, Tor, Lassen, Mats C. Hojbjerg, Skaarup, Kristoffer G., Barge-Caballero, Eduardo, Pouleur, Anne-Catherine, Stolfo, Davide, Sinagra, Gianfranco, Ablasser, Klemens, Muster, Viktoria, Rainer, Peter P., Wallner, Markus, Chiodini, Alessandra, Heiniger, Pascal S., Mikulicic, Fran, Schwaiger, Judith, Winnik, Stephan, Cakmak, Huseyin A., Gaudenzi, Margherita, Mapelli, Massimo, Mattavelli, Irene, Paul, Matthias, Cabac-Pogorevici, Irina, Bouleti, Claire, Lilliu, Marzia, Minoia, Chiara, DAUW, Jeroen, Costa, Jerome, Celik, Ahmet, Mewton, Nathan, Montenegro, Carlos E. L., Matsue, Yuya, Loncar, Goran, Marchel, Michal, Bechlioulis, Aris, Michalis, Lampros, Dorr, Marcus, Prihadi, Edgard, Schoenrath, Felix, Messroghli, Daniel R., MULLENS, Wilfried, Lund, Lars H., Rosano, Giuseppe M. C., Ponikowski, Piotr, Ruschitzka, Frank, and Flammer, Andreas J.
- Subjects
Male ,Cardiac & Cardiovascular Systems ,[SDV]Life Sciences [q-bio] ,Disease ,030204 cardiovascular system & hematology ,0302 clinical medicine ,Interquartile range ,Original Research Articles ,Clinical endpoint ,Original Research Article ,Hospital Mortality ,Registries ,030212 general & internal medicine ,Incidence (epidemiology) ,Cardiovascular disease ,3. Good health ,[SDV] Life Sciences [q-bio] ,Female ,Cardiology and Cardiovascular Medicine ,Life Sciences & Biomedicine ,medicine.medical_specialty ,SARS‐CoV2 ,Heart failure ,CORONAVIRUS DISEASE 2019 ,SARS-CoV2 ,03 medical and health sciences ,COVID‐19 ,Diabetes mellitus ,Internal medicine ,medicine ,Diseases of the circulatory (Cardiovascular) system ,Humans ,Aged ,Retrospective Studies ,Heart Failure ,Science & Technology ,SARS-CoV-2 ,business.industry ,COVID-19 ,Odds ratio ,medicine.disease ,Confidence interval ,Risk factors ,RC666-701 ,Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,Cardiovascular System & Cardiology ,INHIBITORS ,business - Abstract
AIMS: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations. METHODS AND RESULTS: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62-81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44-2.59], P
- Published
- 2021
- Full Text
- View/download PDF
4. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study
- Author
-
Gloria Maccagni, Stefano Giovinazzo, Filippo M. Sarullo, Piergiuseppe Agostoni, Massimo F Piepoli, Marco Metra, Vincenzo Nuzzi, Luca Monzo, Maria Teresa La Rovere, Margherita Gaudenzi, Andrea Pozzi, Massimo Mapelli, Claudia Canale, Lucia Barbieri, Italo Porto, Valentina Carubelli, Gian Battista Danzi, Andrea Mortara, Chiara Tedino, Marco Merlo, Gianfranco Sinagra, Marco Guazzi, Annamaria Iorio, Antonio Bellasi, Francesco Catagnano, Laura Adelaide Dalla Vecchia, Riccardo M. Inciardi, Carlo Lombardi, Daniela Tomasoni, Stefano Carugo, Mattia Di Pasquale, Maurizio Volterrani, Massimiliano Gnecchi, Gregorio Zaccone, Michele Senni, Davide Margonato, Pietro Ameri, Rita Camporotondo, Sergio Leonardi, Tomasoni, D, Inciardi, R, Lombardi, C, Tedino, C, Agostoni, P, Ameri, P, Barbieri, L, Bellasi, A, Camporotondo, R, Canale, C, Carubelli, V, Carugo, S, Catagnano, F, Dalla Vecchia, L, Danzi, G, Di Pasquale, M, Gaudenzi, M, Giovinazzo, S, Gnecchi, M, Iorio, A, La Rovere, M, Leonardi, S, Maccagni, G, Mapelli, M, Margonato, D, Merlo, M, Monzo, L, Mortara, A, Nuzzi, V, Piepoli, M, Porto, I, Pozzi, A, Sarullo, F, Sinagra, G, Volterrani, M, Zaccone, G, Guazzi, M, Senni, M, and Metra, M
- Subjects
Male ,Comorbidity ,030204 cardiovascular system & hematology ,Severity of Illness Index ,0302 clinical medicine ,Adrenal Cortex Hormones ,Interquartile range ,COVID-19 ,Heart failure ,Outcome ,SARS-CoV-2 Infection ,Acute Disease ,Age Factors ,Aged ,Aged, 80 and over ,Anticoagulants ,Blood Gas Analysis ,Chronic Disease ,Disease Progression ,Female ,Heart Failure ,Heparin ,Humans ,Italy ,Length of Stay ,Middle Aged ,Multiple Organ Failure ,Multivariate Analysis ,Partial Pressure ,Prognosis ,Proportional Hazards Models ,Protective Factors ,SARS-CoV-2 ,Sepsis ,Hospital Mortality ,Fraction of inspired oxygen ,heart failure ,outcome ,acute disease ,adrenal cortex hormones ,age factors ,aged ,aged, 80 and over ,anticoagulants ,blood gas analysis ,chronic disease ,comorbidity ,disease progression ,female ,heparin ,humans ,italy ,length of stay ,male ,middle aged ,multiple organ failure ,multivariate analysis ,partial pressure ,prognosis ,proportional hazards models ,protective factors ,sepsis ,severity of illness index ,hospital mortality ,80 and over ,Oxygen saturation (medicine) ,Hazard ratio ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,03 medical and health sciences ,Internal medicine ,medicine ,business.industry ,Proportional hazards model ,medicine.disease ,Confidence interval ,business - Abstract
Aims: To assess the prognostic value of a history of heart failure (HF) in patients with coronavirus disease 2019 (COVID-19). Methods and results: We enrolled 692 consecutive patients admitted for COVID-19 in 13 Italian cardiology centres between 1 March and 9 April 2020. Mean age was 67.4± 13.2 years, 69.5% of patients were males, 90 (13.0%) had a history of HF, median hospitalization length was 14 days (interquartile range 9–24). In-hospital death occurred in 37 of 90 patients (41.1%) with HF history vs. 126 of those with no HF history (20.9%). The increased risk of death associated with HF history remained significant after adjustment for clinical variables related to COVID-19 and HF severity, including comorbidities, oxygen saturation, lymphocyte count and plasma troponin [adjusted hazard ratio (HR) for death: 2.25; 95% confidence interval (CI) 1.26–4.02; P= 0.006 at multivariable Cox regression model including 404 patients]. Patients with a history of HF also had more in-hospital complications including. acute HF (33.3% vs. 5.1%, P< 0.001), acute renal failure (28.1% vs. 12.9%, P< 0.001), multiorgan failure (15.9% vs. 5.8%, P= 0.004) and sepsis (18.4% vs. 8.9%, P= 0.006). Other independent predictors of outcome were age, sex, oxygen saturation and oxygen partial pressure at arterial gas analysis/fraction of inspired oxygen ratio (PaO2/FiO2). In-hospital treatment with corticosteroids and heparin had beneficial effects (adjusted HR for death: 0.46; 95% CI 0.29–0.74; P= 0.001; n= 404 for corticosteroids, and adjusted HR 0.41; 95% CI 0.25–0.67; P< 0.001; n= 364 for heparin). Conclusions: Hospitalized patients with COVID-19 and a history of HF have an extremely poor outcome with higher mortality and in-hospital complications. HF history is an independent predictor of increased in-hospital mortality.
- Published
- 2020
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.